Not available
Quote | Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
Last: | $23.29 |
---|---|
Change Percent: | 0.17% |
Open: | $23.74 |
Close: | $23.29 |
High: | $23.76 |
Low: | $22.89 |
Volume: | 813,628 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may acc...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial ( NCT06209177 ) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement ...
Message Board Posts | Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ARWR News Article - Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday | whytestocks | investorshangout | 04/25/2023 3:35:46 PM |
$ARWR still ascending. | MiamiGent | investorshub | 01/13/2023 4:36:57 PM |
whytestocks: $ARWR News Article - Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment | whytestocks | investorshangout | 12/20/2022 4:25:49 PM |
Arrowhead is an amazing company. Gene silencing | jimmy667 | investorshub | 10/22/2022 8:11:09 AM |
whytestocks: $ARWR News Article - 5 Top Biotech Stocks To Watch In July 2022 | whytestocks | investorshangout | 06/30/2022 6:55:50 PM |
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may acc...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial ( NCT06209177 ) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement ...
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) , a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected t...